Close Menu

SQI Imaware Celiac Disease Test

Dec 10, 2018

SQI Diagnostics has launched the Imaware home-based test for celicac disease developed by Microdrop. The test is run on SQI's automated system. Other Imaware tests running on the SQI platform are expected to launch in 2019, including a home-based test for rheumatoid arthritis, SQI said.

More Like This

Jul 17, 2019

Bio-Techne 32X8 Cartridge for the Ella Platform

Bio-Techne announced the launch of a new eight-plex cartridge format for its ProteinSimple-branded Ella automated immunoassay platform. The 32x8 cartridge for Ella enables users to build panels of up to eight analytes, selected from a pool of pre-validated analytes that are putative biomarkers for a variety of diseases, including inflammation and cancer. These multiplex assays are validated to the same high standards of a single-plex assay, allowing users to seamlessly transition between plex levels and cartridge formats, the firm said.

Jul 16, 2019

Abbott Configurable Molecular Workflows

Abbott launched a laboratory information management system, Starlims Life Sciences Solution 11.1, to help manage complex sample and testing workflows, and to help drive data safety and integrity throughout the testing lifecycle.

Starlims Life Sciences Solution 11.1 is designed for pre-clinical, clinical research, biorepository, animal health, molecular, specialty diagnostics, and academic research applications that manage and test clinical samples.

Abbott said that the solution gives customers the flexibility to self-configure a wide choice of assays in an integrated fashion within the firm's biorepository, inventory, and quality control products.

Jul 16, 2019

OptraScan OS-SiA Digital Scanner

OptraScan has launched the OS-SiA, an AI-enabled digital scanner that automatically and simultaneously scans and analyzes tissue slides. The scanner can be embedded in OptraScan's series of cloud-enabled 15- to 120-slide brightfield scanners. According to the company, the analyzed information serves as a reference heatmap to guide users to a high level view of the tumor, rare events, or other areas of importance. The digitized images taken from OS-SiA can be viewed in local, web-based, mobility-based image viewers.

Jul 15, 2019

NanoString Alzheimer’s Disease Research Panels

Seattle-based NanoString Technologies has developed a set of new nCounter gene expression panels for use in Alzheimer's disease research, which it created and tested in collaboration with the MODEL-AD consortium. The two panels — one for use in mouse studies and another for human studies — measure the expression of 770 genes covering 30 modules discovered in a recent study of human brain tissue. The firm noted that both panels are available for purchase through its website.

Jul 12, 2019

PerkinElmer Anti-Borrelia, Anti-EBV/EBNA Assays

PerkinElmer launched two assays for detecting anti-Borrelia (Lyme diesase) and anti-EBV/EBNA (Epstein-Barr-Virus) antibodies. Both assays were CE marked in late May and run on the Euroimmun RA Analyzer 10 system, an automation solution for small and medium-sized labs. It also complements high-throughput devices in large labs. 

Jul 02, 2019

ZeptoMetrix NATtrol Respiratory Verification Panel

ZeptoMetrix has released the NATtrol Respiratory Verification Panel, a 20-member respiratory panel for use by laboratories in QC applications with molecular diagnostics for infectious disease testing. ZeptoMetrix was founded in 1999 and is based in Buffalo, New York.

Jun 28, 2019

BillionToOne Unity Prenatal Screen

BillionToOne has commercially launched its Unity prenatal screening assay. According to BillionToOne, the assay is powered by its molecular counting technology and is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy, and sickle cell disease using only one tube of the mother's blood. The firm said it will make the test available at select clinics through its early access program, with plans for a broader commercial launch later this year. 

Jun 25, 2019

Co-Diagnostics Zika, Dengue, Chikungunya Multiplex Test

Co-Diagnostics announced the launch of its Logix Smart ZDC multiplex test at the 64th Annual 2019 Caribbean Public Health Agency Health Research Conference in Trinidad and Tobago.

The firm designed the ZDC multiplex test to detect the presence of Zika, dengue, and chikungunya within a single polymerase chain reaction assay. The firm said that the performance of the test confirms the heightened specificity provided by its CoPrimer platform in multiplex PCR applications. Co-Diagnostics received CE marking for the ZDC multiplex test in the first quarter after validating its performance, permitting its marketing throughout the European Community, Latin America, the Caribbean Basin, and other jurisdictions that accept the CE designation.

Jun 24, 2019

Agilent NovoCyte Advanteon Flow Cytometer

Agilent Technologies launched the NovoCyte Advanteon Flow Cytometer. It is the first product from Agilent's recently acquired ACEA Biosciences. the NovoCyte Advanteon can be configured with, two, or three lasers and up to 21 fluorescence channels. It also has a 7.2 log dynamic range, and fully automated compensation features.

Jun 24, 2019

Cytek Biosciences Five-Laser Flow Cytometer

Cytek Biosciences launched the latest version of the Cytek Aurora advanced flow cytometry system, now available with five lasers to allow users to see more than 30 colors from a single sample. Among the features of the new instrument is that no optical filters need to be changed and any fluorochrome excited by the onboard lasers can be used. Sensitivity is improved as is resolution of dim and rare populations, Cytek added. 
Jun 19, 2019

Proscia's DermAI Digital Pathology Application

Proscia has launched DermAI, its first in a series of artificial intelligence applications for pathologists. DermAI, a module on the firm's Concentriq digital platform, uses deep learning to prescreen and classify skin biopsies, aiming to help reduce diagnostic errors and improve laboratory quality and efficiency, Proscia said. The artificial intelligence application reads and automatically classifies hundreds of variants of skin diseases into prediagnostic categories.

Jun 18, 2019

Biocept NGS Breast Panel

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations. 

Jun 17, 2019

Abbott Afinion HbA1c Dx Assay

Abbott announced that its Afinion HbA1c Dx assay is available for use on its Afinion 2 and Afinion AS100 analyzers. The Afinion HbA1c Dx assay is the first rapid point-of-care test cleared by the US Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the condition, Abbott said.

The test delivers accurate and precise HbA1c results in three minutes, enabling clinicians to diagnose patients and help them formulate individualized care plans during a single doctor's office visit, the firm said.

Jun 12, 2019

Patients Choice Laboratories UTI+ Test

Patients Choice Laboratories has launched the UTI+ molecular test for urinary tract infections. The Indianapolis-based company said the new test is part of its goal to be a full-service lab. It added that its gene- and molecular-based technologies provides uropathogenic and antibiotic resistance testing results within six hours after specimen receipt compared to up to three days with urinalysis by culturing. 

Jun 04, 2019

Illumina VeriSeq NIPT Solution v2

Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version expands the range of chromosomal and sub-chromosomal conditions associated with birth defects that laboratories can screen for. The assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. It is available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.